View larger version (58K):
[in this window]
[in a new window]
|
Figure 1. Study flow diagram.
Primary exclusion criteria are listed; some patients met more than 1 exclusion criterion. One patient assigned to adefovir withdrew before initiation of treatment; thus, the intention-to-treat sample was 135 patients, of whom 45, 44, and 46 were assigned to receive telbivudine, adefovir, or adefovir for 24 weeks and then telbivudine for the remaining 28 weeks, respectively. One adefovir recipient withdrew before the week-24 analysis; 1 additional adefovir recipient and 2 telbivudine recipients withdrew before the week-52 analysis. ALT = alanine aminotransferase; HBeAg = hepatitis B e antigen; HBV = hepatitis B virus.
|
